Tagged with oncology

Europe Janssen’s EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access cutting-edge cancer medicines.   Recent advances in medical science are the driving force behind the research and successful development of innovative cancer treatments in Europe. By targeting…

China Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019.   I did not want to work on an antibody similar to the dozens already in clinical trials, I wanted to…

Taiwan Dr Mien-Chie Hung, president of China Medical University, shares his personal mission upon taking the role only three months ago. Dr Hung also elaborates on the research strengths of CMU and goes on to give his view on what role Taiwan and the university can play in tackling the Asian…

Spain Stefanie Granado, director general of Takeda Iberia recounts the opportunities available for Takeda in Spain following its acquisition of Shire. She also discusses Takeda’s local acquisition of TiGenix, handing Takeda stem cell production capabilities, and how this makes Spain a key market and hub for the company.   We continue…

Taiwan Dr Tse Wen Chang, founder of Immunwork, gives an update on the preclinical development process of the company’s revolutionary T-E pharmaceutical products and goes on to give his expert insights on the dynamics at play within Taiwan’s biotech and biomedical industries.   Whether Taiwan’s biomedical industry can be robust will…

Taiwan Dr James Chih-Hsin Yang, director of National Taiwan University Hospital’s department of oncology, speaks about oncology in Taiwan and the role that the NTU network plays in the island’s oncology space. Dr Yang goes on to share his insights on key trends shaping modern and future cancer treatment.   We…

Egypt Dr Mohamed Khattab, the newly appointed chairman and managing director of Sedico, lifts the lid on his vision for the company being a leader in biotechnology and oncology in Egypt. He reveals his plan for raising the company’s profile through branding and highlights Sedico’s ambition to export to markets in…

China PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in China, but local players are already releasing their own drugs, sometimes at a third of the price. This represents a…

China Carsten Lu of Chinese biotech Adlai Nortye outlines his strategy for navigating a crowded immuno-oncology field in China, his partnership strategy, and the firm’s early move to establish a footprint in the USA.   The Chinese biotech industry itself is already moving at supersonic speeds to catch up to international…

France Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging markets strategy, while reaffirming Pierre Fabre’s commitment to France’s healthcare innovation ecosystem. As illustrated by the group’s new motto ‘Taking…

Taiwan Grace Yeh, president and founder of PharmaEngine, gives an update on the company’s recent growth and development of their second nanomedicine cancer treatment. Yeh goes on to explain the unique positioning of nanomedicine within oncology and Taiwan’s role as an active participant in the global fight against cancer.   PharmaEngine…

Europe From her vantage point as associate vice president for MSD’s Central & Eastern Europe (CEE) cluster, Gabriele Grom outlines the disparity that still exists in terms of access to cancer treatments across Europe and what must be done to bridge this gap.   Despite the existence of innovative treatments, cancer…